Source comparison
Why Pulsatility Is the Whole Point: Secretagogue Versus Exogenous Hormone
A network diagram of tesamorelin’s action is incomplete without the concept of pulsatility, because it is the feature that distinguishes engaging the axis from overriding it. Physiological GH secretion is not a steady drip; it is released in discrete bursts, p
This comparison does not assign a generated winner or score.
- A network diagram of tesamorelin’s action is incomplete without the concept of pulsatility, because it is the feature that distinguishes engaging the axis from overriding it. Physiological GH secretion is not a steady drip; it is released in discrete bursts, predominantly during slow-wave sleep, separated by troughs during which GH falls to nearly undetectable levels.5 This pulsatile pattern is not incidental. Target tissues read the pattern of GH exposure, not merely the average concentration: the peaks drive certain gene programs while the intervening troughs allow receptors to reset and prevent the desensitization that continuous exposure would cause.5
- Because tesamorelin works by prompting the pituitary to release its own GH, it amplifies these endogenous pulses rather than replacing them with a flat, supraphysiological plateau.3 The somatotroph still answers to hypothalamic somatostatin, which periodically brakes secretion, and to the negative feedback exerted by GH and IGF-1 themselves. The consequence is a GH profile that is higher in amplitude but still recognizably rhythmic and still subject to shutdown. This is the mechanistic argument — and it is a mechanistic argument, not a proven clinical-superiority claim — for why a GHRH analog might produce a more “physiological” downstream signature than an equivalent exposure to injected recombinant GH, which delivers hormone on the pharmacokinetics of the injection rather than the biology of the pituitary.
- The practical relevance for the IGF-1 question is subtle but important. IGF-1 is produced largely in the liver in response to GH, and because IGF-1 has a long circulating half-life (it travels bound to IGF-binding proteins and the acid-labile subunit), the pulsatile GH signal is effectively integrated into a smoother, more stable IGF-1 concentration. In other words, the spiky upstream GH signal is low-pass-filtered by hepatic IGF-1 biology into the steady rise clinicians measure in a morning blood draw. This is why IGF-1, rather than GH itself, is the biomarker used to track tesamorelin’s effect and safety: a single GH level is nearly meaningless given the pulses, whereas IGF-1 reflects the time-averaged strength of the whole axis.1
- The same pulsatility logic is what motivates interest in other endogenous-GH strategies across the peptide field. Ghrelin-receptor secretagogues, GHRH fragments such as sermorelin, and combination approaches are all, in principle, attempts to raise GH output while keeping the pituitary in the loop; the broader family and how these compounds are catalogued for research reference appears in the site’s central dosages index. Tesamorelin is distinguished within that group less by a unique mechanism than by the depth of its human evidence in one specific indication.